Clinical Trial

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

Study acronym: TRIGGERCD8
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-15; most recent amendment 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2024-07-09
Trial Details
NCT Number NCT06468358
Lead Sponsor L & L Bio Co., Ltd., Ningbo, China
Collaborators: Shanghai East Hospital
Conditions Solid Tumor
Enrollment 194 participants
Start Date 2024-06-19
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-11